Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®

被引：104

作者：

Kaku, Kohei ^{[1
]}

Lee, Jisoo ^{[2
]}

Mattheus, Michaela ^{[2
]}

Kaspers, Stefan ^{[2
]}

George, Jyothis ^{[3
]}

Woerle, Hans-Juergen ^{[2
]}

Aizenberg, D. ^{[4
]}

Ulla, M. ^{[5
]}

Waitman, J. ^{[6
]}

De Loredo, L. ^{[7
,8
]}

Farias, J. ^{[9
]}

Fideleff, H. ^{[9
]}

Lagrutta, M. ^{[10
]}

Maldonado, N. ^{[11
]}

Colombo, H. ^{[12
]}

Ferre Pacora, F. ^{[13
]}

Wasserman, A. ^{[14
]}

Maffei, L. ^{[15
]}

Lehman, R. ^{[16
]}

Selvanayagam, J. ^{[17
]}

d'Emden, M. ^{[18
]}

Fasching, P. ^{[19
]}

Paulweber, B. ^{[20
]}

Toplak, H. ^{[21
]}

Luger, A. ^{[22
]}

Drexel, H. ^{[23
]}

Prager, R. ^{[24
]}

Schnack, C. ^{[25
]}

Schernthaner, G. ^{[25
,26
]}

Fliesser-Goerzer, E.

Kaser, S. ^{[27
]}

Scheen, A. ^{[28
]}

Van Gaal, L. ^{[29
]}

Hollanders, G.

Kockaerts, Y. ^{[30
]}

Capiau, L.

Chachati, A. ^{[31
]}

Persu, A. ^{[32
]}

Hermans, M. ^{[32
]}

Vantroyen, D. ^{[33
]}

Vercammen, C. ^{[34
]}

Van de Borne, P. ^{[35
]}

Mathieu, C. ^{[36
]}

Benhalima, K. ^{[36
]}

Lienart, F. ^{[37
]}

Mortelmans, J.

Strivay, M. ^{[38
]}

Vereecken, G.

Keymeulen, B. ^{[39
]}

Lamkanfi, F. ^{[39
]}

机构：

[1] Kawasaki Med Sch, Dept Gen Internal Med, 577 Matsushima, Kurashiki, Okayama 7010192, Japan

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[4] Ctr Med Viamonte, Buenos Aires, DF, Argentina

[5] ILAIMCEOM, Cordoba, Cba, Argentina

[6] Ctr Diabetol Dr Waitman, Cordoba, Cba, Argentina

[7] Hosp Privado Ctr Med Cordoba SA, Cordoba, Cba, Argentina

[8] Parque Velez Sarfield, Cordoba, Cba, Argentina

[9] Sanatorio Guemes Hosp Privado, Buenos Aires, DF, Argentina

[10] Inst Invest Clin, Rosario, Santa Fe, Argentina

[11] Ctr Med Alta Complejidad, Rosario, Santa Fe, Argentina

[12] Clin Privada Colombo, Cordoba, Co, Argentina

[13] Ctr Med Colon, Cordoba, Co, Argentina

[14] Fepreva, Buenos Aires, DF, Argentina

[15] Consultorios Asociados Endocrinol & Invest Clin, Buenos Aires, DF, Argentina

[16] Adelaide Med Res, Ashford, SA, Australia

[17] Heart & Vasc Inst, Fullarton, SA, Australia

[18] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[19] Wilhelminenspital Wien, Vienna, Austria

[20] LKH Salzburg, St Johanns Spital, Salzburg, Austria

[21] Med Univ Graz, Graz, Austria

[22] Univ Klin Innere Med III, Vienna, Austria

[23] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[24] Krankenhaus Hietzing NZR, Vienna, Austria

[25] Krankenanstalt Rudolfstiftung Wien, Semmelweis Frauenklin, Vienna, Austria

[26] Univ Klin Innere Med II, Vienna, Austria

[27] Univ Klin Innsbruck, Innsbruck, Austria

[28] Ctr Hosp Univ Liege, Liege, Belgium

[29] UZA, Edegem, Belgium

[30] Ziekenhuis Oost Limburg, Genk, Belgium

[31] CHR Huy, Huy, Belgium

[32] Clin Univ St Luc, Brussels, Belgium

[33] Huisartsenpraktijk Hygeia, Hasselt, Belgium

[34] Imelda ZH Bonheiden, Bonheiden, Belgium

[35] Hop Univ Erasme, Brussels, Belgium

[36] Univ Hosp Gasthuisberg, Leuven, Belgium

[37] CHU Tivoli, La Louviere, Belgium

[38] CHR Citadelle, Site Citadelle, Liege, Belgium

[39] UZ Brussels, Brussels, Belgium

[40] Hosp Sao Paulo UNIFESP, Villa Clementino, SP, Brazil

[41] Ctr Pesquisas Clin Ltda, Higienopolis, SP, Brazil

[42] Hosp Rim Hipertensao, Vila Clementino, SP, Brazil

[43] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil

[44] Blumenau Serv Med SC Ltda, Vila Leopoldina, SP, Brazil

[45] Irmandade Santa Casa Misericordia Sao Paulo, Vila Albuquerque, SP, Brazil

[46] Hosp Guilherme Alvaro, Ctr Pesquisas Clin, Boqueirao, ST, Brazil

[47] Hosp Mae Deus, Porto Alegre, RS, Brazil

[48] Hosp Geral Goiania, Goiania, Go, Brazil

[49] FMUSP, Hosp Clin Sao Paulo, Sao Paulo, Brazil

[50] Univ Ribeirao Preto, Hosp Elect Bonini, Ribeirao Preto, Brazil

来源：

CIRCULATION JOURNAL | 2017年 / 81卷 / 02期

关键词：

Diabetes mellitus; Mortality; Race; Sodium-glucose cotransporter 2; Treatment outcomes; INHIBITION;

D O I：

10.1253/circj.CJ-16-1148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race. Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48-0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population. Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

引用

页码：227 / +

页数：11

共 50 条

[1] Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
Kadowaki, Takashi
Nangaku, Masaomi
Hantel, Stefan
Okamura, Tomoo
von Eynatten, Maximilian
Wanner, Christoph
Koitka-Weber, Audrey
JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (03) : 760 - 770
[2] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
Bernard Zinman
Silvio E. Inzucchi
Christoph Wanner
Uwe Hehnke
Jyothis T. George
Odd Erik Johansen
David Fitchett
Diabetologia, 2018, 61 : 1522 - 1527
[3] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Fitchett, David
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Hantel, Stefan
Salsali, Afshin
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
[4] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Verma, Subodh
Mazer, C. David
Al-Omran, Mohammed
Inzucchi, Silvio E.
Fitchett, David
Hehnke, Uwe
George, Jyothis T.
Zinman, Bernard
CIRCULATION, 2018, 137 (04) : 405 - 407
[5] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
Zinman, Bernard
Inzucchi, Silvio E.
Wanner, Christoph
Hehnke, Uwe
George, Jyothis T.
Johansen, Odd Erik
Fitchett, David
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
Strivay, M.
Vereecken, G.
Keymeulen, B.
DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
[6] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
Verma, Subodh
Mazer, C. David
Bhatt, Deepak L.
Raj, Satish R.
Yan, Andrew T.
Verma, Atul
Ferrannini, Ele
Simons, Gudrun
Lee, Jisoo
Zinman, Bernard
George, Jyothis T.
Fitchett, David
DIABETES CARE, 2019, 42 (03) : E42 - E44
[7] Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
DIABETES, 2020, 69
[8] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
Sharma, Abhinav
Inzucchi, Silvio E.
Testani, Jeffrey
Ofstad, Anne-Pernille
Fitchett, David
Mattheus, Michaela
Verma, Subodh
Zannad, Faiez
Wanner, Christoph
Kraus, Bettina J.
JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
[9] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
Fisher, Miles
BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141
[10] Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
Kansal, A.
Reifsnider, O. S.
Proskorovsky, I.
Zheng, Y.
Pfarr, E.
George, J. T.
Kandaswamy, P.
Ruffolo, A.
DIABETIC MEDICINE, 2019, 36 (11) : 1494 - 1502

← 1 2 3 4 5 →